

**Remarks**

This Supplemental Amendment B After Final is respectfully submitted in response to the telephonic interview with the Examiner requesting that Applicants consider further amendments to the claims to correct minor informalities and to place the application in condition for allowance. Therefore, this amendment further supplements the Amendment After Final filed July 6, 2010 and the Supplemental Amendment B After Final filed July 20, 2010.

In response, Applicants have amended claim 56 to remove recited compounds that are no longer covered by claim 52 from which claim 56 indirectly depends. Applicants have also amended claim 90 to correct the structure of formula 1 and to remove reference to R<sub>g</sub> in the claim.

Regarding a proposed amendment to claim 64, Applicants respectfully submit that no new matter is added by the clarification that each of the one or more host immune modulators is selected from the group consisting of, *inter alia*, a vaccine optionally comprising an antigen and an adjuvant. The original claim 64 recited a vaccine and a vaccine comprising an antigen and an adjuvant which is supported in the specification at, for example, page 73, lines 24-30. It is implicit in the disclosure of a vaccine and a vaccine comprising an antigen and an adjuvant that the disclosure of the first "vaccine" with no other modifiers is distinguished from the second "vaccine" on the basis that the first "vaccine" does not comprise an antigen and an adjuvant. It would be redundant to construe both terms as comprising an antigen and an adjuvant. Therefore, the amendment of the original claim 64 to recite that the vaccine optionally comprises an antigen and an adjuvant is merely a clarification of what is implicit in the disclosure and, thus, does not constitute new matter.

Accordingly, Applicants respectfully submit that pending claims 28, 52-57, 62-71, 74, 90-92, 96 and 97 are in condition for allowance.

\* \* \* \* \*

Applicants believe that they do not owe any other fee(s) for this filing. If, however, Applicants do owe any such fee(s), the Patent Office is hereby authorized to charge those fee(s) to Deposit Account No. **01-0025**. In addition, if there is ever any fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Patent Office is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **01-0025**.

Applicants respectfully submit that the application is in condition for allowance, and request that it be allowed. Applicants request that the Examiner call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

U.S. Patent Application No. 10/699,513  
Response to March 5, 2010 Office Action  
August 9, 2010

Respectfully submitted,  
Pratt et al.

/Bradley E. Davis, PTO Reg. No. 56,727/

---

Bradley E. Davis, PTO Reg. No. 56,727  
Abbott Laboratories  
Dept. 0377, Bldg. AP6A-1  
100 Abbott Park Road  
Abbott Park, IL 60064  
(847) 936-7868 (tel)  
(847) 938-2623 (fax)